Joseph Lehar

Summary

Publications

  1. pmc Synergistic drug combinations tend to improve therapeutically relevant selectivity
    Joseph Lehar
    CombinatoRx Inc, Cambridge, Massachusetts, USA
    Nat Biotechnol 27:659-66. 2009
  2. pmc Chemical combination effects predict connectivity in biological systems
    Joseph Lehar
    CombinatoRx, Incorporated, Cambridge, MA 02142, USA
    Mol Syst Biol 3:80. 2007
  3. pmc Combination chemical genetics
    Joseph Lehar
    CombinatoRx Incorporated, 245 First Street, Cambridge, Massachusetts 02142, USA
    Nat Chem Biol 4:674-81. 2008
  4. pmc Chemical combinations elucidate pathway interactions and regulation relevant to Hepatitis C replication
    Christopher M Owens
    CombinatoRx, Incorporated, Cambridge, MA 02142, USA
    Mol Syst Biol 6:375. 2010
  5. pmc Systematic discovery of multicomponent therapeutics
    Alexis A Borisy
    CombinatoRx Incorporated, 650 Albany Street, Boston, MA 02118, USA
    Proc Natl Acad Sci U S A 100:7977-82. 2003
  6. ncbi Multi-target therapeutics: when the whole is greater than the sum of the parts
    Grant R Zimmermann
    CombinatoRx Inc, 245 First Street, Cambridge, MA 02142, USA
    Drug Discov Today 12:34-42. 2007
  7. pmc RAD001 enhances the potency of BEZ235 to inhibit mTOR signaling and tumor growth
    Beat Nyfeler
    Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, United States of America
    PLoS ONE 7:e48548. 2012
  8. pmc The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
    Jordi Barretina
    The Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, USA
    Nature 483:603-7. 2012
  9. pmc High-order combination effects and biological robustness
    Joseph Lehar
    Discovery, CombinatoRx Inc, Cambridge, MA 02142, USA
    Mol Syst Biol 4:215. 2008
  10. doi Identification of synergistic combinations of F508del cystic fibrosis transmembrane conductance regulator (CFTR) modulators
    Stephen Lin
    Zalicus, Inc, Cambridge, Massachusetts, USA
    Assay Drug Dev Technol 8:669-84. 2010

Collaborators

Detail Information

Publications10

  1. pmc Synergistic drug combinations tend to improve therapeutically relevant selectivity
    Joseph Lehar
    CombinatoRx Inc, Cambridge, Massachusetts, USA
    Nat Biotechnol 27:659-66. 2009
    ..The context specificity of synergistic combinations creates many opportunities for therapeutically relevant selectivity and enables improved control of complex biological systems...
  2. pmc Chemical combination effects predict connectivity in biological systems
    Joseph Lehar
    CombinatoRx, Incorporated, Cambridge, MA 02142, USA
    Mol Syst Biol 3:80. 2007
    ..This response surface methodology may even apply to non-biological systems where responses to targeted perturbations can be measured...
  3. pmc Combination chemical genetics
    Joseph Lehar
    CombinatoRx Incorporated, 245 First Street, Cambridge, Massachusetts 02142, USA
    Nat Chem Biol 4:674-81. 2008
    ....
  4. pmc Chemical combinations elucidate pathway interactions and regulation relevant to Hepatitis C replication
    Christopher M Owens
    CombinatoRx, Incorporated, Cambridge, MA 02142, USA
    Mol Syst Biol 6:375. 2010
    ..Our findings show how combination chemical genetics can reveal critical pathway connections relevant to viral replication, and can identify potential treatments with an increased therapeutic window...
  5. pmc Systematic discovery of multicomponent therapeutics
    Alexis A Borisy
    CombinatoRx Incorporated, 650 Albany Street, Boston, MA 02118, USA
    Proc Natl Acad Sci U S A 100:7977-82. 2003
    ..Systematic combination screening may ultimately be useful for exploring the connectivity of biological pathways and, when performed with reference-listed drugs, may result in the discovery of new combination drug regimens...
  6. ncbi Multi-target therapeutics: when the whole is greater than the sum of the parts
    Grant R Zimmermann
    CombinatoRx Inc, 245 First Street, Cambridge, MA 02142, USA
    Drug Discov Today 12:34-42. 2007
    ....
  7. pmc RAD001 enhances the potency of BEZ235 to inhibit mTOR signaling and tumor growth
    Beat Nyfeler
    Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, United States of America
    PLoS ONE 7:e48548. 2012
    ..This is relevant since RAD001 is relatively well tolerated in patients while the toxicity profiles of ATP-competitive mTOR inhibitors are currently unknown...
  8. pmc The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
    Jordi Barretina
    The Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, USA
    Nature 483:603-7. 2012
    ..The generation of genetic predictions of drug response in the preclinical setting and their incorporation into cancer clinical trial design could speed the emergence of 'personalized' therapeutic regimens...
  9. pmc High-order combination effects and biological robustness
    Joseph Lehar
    Discovery, CombinatoRx Inc, Cambridge, MA 02142, USA
    Mol Syst Biol 4:215. 2008
    ..Such studies would also reinforce the growing appreciation that biological systems are best manipulated not by targeting a single protein, but by modulating the set of many nodes that can selectively control a system's functional state...
  10. doi Identification of synergistic combinations of F508del cystic fibrosis transmembrane conductance regulator (CFTR) modulators
    Stephen Lin
    Zalicus, Inc, Cambridge, Massachusetts, USA
    Assay Drug Dev Technol 8:669-84. 2010
    ....